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We evaluated prognostic factors for leptospirosis in 
168 consecutive hospitalized patients in Guadeloupe. Fac-
tors independently associated with severity included chronic 
hypertension or chronic alcoholism, late initiation of antibac-
terial therapy, abnormal chest auscultation results, icterus, 
oligoanuria, disorders of consciousness, elevated aspartate 
aminotransferase levels, hyperamylasemia, and Leptospira 
interrogans serovar Icterohemorrhagiae.
L
eptospirosis is a reemerging infectious disease in tropi-
cal and subtropical regions (1). In Guadeloupe, it has 
long been a major public health concern. Its incidence rate 
was ≈5.5/100,000 inhabitants per year from 1991 through 
2002. Since 2003, this rate has greatly increased, peaking at 
41.2/100,000 inhabitants in 2004 (2,3). The clinical features 
of leptospirosis vary and may progress to multiorgan fail-
ure and death (4). Initial clinical symptoms and laboratory 
test results associated with severe forms remain unclear. 
In this study, we focused on severe forms and determined 
prognostic factors that may help physicians in the early 
management of leptospirosis. We also characterized reser-
voir hosts by identifying the serovars of infecting strains. 
These ﬁ  ndings will help establish appropriate control and 
prevention measures.
The Study
This study was conducted in the hospital of Pointe-à-
Pitre (1,100 beds), a tertiary referral center for Guadeloupe 
and neighboring islands. The ethical committee of the hos-
pital approved the study. All consecutive patients hospital-
ized from January 2003 and through December 2004 with 
conﬁ   rmed leptospirosis were included; patients admitted 
to Guadeloupe’s other hospital (200 beds) were excluded. 
Leptospirosis was conﬁ   rmed if 1 blood culture yielded 
Lesptospira spp. or if speciﬁ  c antibodies were detected with 
either a single titer of >400 with the microscopic aggluti-
nation test (MAT) and an in-house enzyme immunoassay 
(EIA) with an immunoglobulin (Ig) M titer >400 (5) or at 
least a 4-fold increase in the MAT titer between the acute 
and convalescent phases. Cases were considered severe if 
dialysis (in case of oliguria) or mechanical ventilation was 
required or if the patient died. Leptospira serovars were iso-
lated and identiﬁ  ed as previously described (3). Epidemio-
logic, clinical, and laboratory data were collected retrospec-
tively from medical records taken at patient’s admission. 
Data were analyzed by using Epi Info (Centers for Disease 
Control and Prevention, Atlanta, GA, USA). A multiple 
stepwise logistic regression analysis (SPSS, Chicago, IL, 
USA) was performed for variables with a p value <0.2.
During the 2-year period, leptospirosis was diagnosed 
in 168 hospitalized patients. A total of 132 case-patients 
had speciﬁ  c antibodies (49 had a single MAT titer >400 
and EIA IgM titer >400, and 83 showed a 4-fold increase 
in the MAT titer in paired serum samples); 36 cases were 
conﬁ  rmed only by culture. Of the 132 case-patients testing 
positive for antibody, 19 were also positive for bacterial 
culture. All but 2 case-patients were residents of Guade-
loupe; the other 2 were a tourist from Paris and a resident of 
the Dominica. The ethnic distribution of the study popula-
tion was similar to that of the Guadeloupean population.
We assessed patients’ demographic, epidemiologic, 
and clinical characteristics (Table 1). Twenty-four (14%) 
cases were considered to be severe: 6 (25%) of these were 
fatal. Female case-patients were signiﬁ  cantly older than 
male case-patients (mean 58.5 ± 17.9 and 47 ± 15.9 years, 
respectively; p = 0.01). Chronic alcoholism was common 
(39%), especially among the 6 case-patients who died 
(67%). Chronic hypertension was also frequent (32%) (Ta-
ble 1). The most common symptoms were myalgia (95%), 
headache (77%), digestive disorders (63%), fever (57%), 
abdominal pain (52%), and icterus (49%). Alveolar inﬁ  l-
trates was the most common feature, accounting for 9 (41%) 
of 22 anomalies observed in the lung by chest radiograph, 
followed by interstitial pattern (27%) and pleural suffusion 
(18%). Six case-patients with severe disease had cardiac 
complications: 2 had pericarditis conﬁ  rmed by echocar-
diography, 2 had ischemic cardiac shock, and 2 myocar-
diopathy and myocarditis. Tomodensitometry or ultra-
sonography showed acute pancreatitis in 10 case-patients, 
of whom 6 had chronic alcoholism and 3 had severe dis-
ease. Thrombocytopenia (<150 × 109 cells/L) was common 
(90% of case-patients), with severe thrombocytopenia (<50 
× 109 cells/L) observed in 19% of case-patients (Table 2). 
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DOI: 10.3201/eid1602.090139Hepatic cytolysis (alanine aminotransferase level >119 U/L 
or aspartate aminotransferase level >102 U/L) was found 
in 45% of case-patients. One ﬁ  fth of case-patients exhib-
ited rhabdomyolysis with creatinine phosphokinase levels 
>1,000 U/L (Table 2). The L. interrogans serovar Icterohe-
morrhagiae was found in 18 (45%) of the 40 case-patients 
for whom serovars were identiﬁ  ed. The closely related L. 
borgpetersenii serovars Arborea and Castellonis accounted 
for 35% of identiﬁ  ed strains (Table 2).
Univariate analysis showed that, after stratiﬁ  cation for 
sex, severity was associated with age for women but not for 
men. Neither occupation (farming, livestock farming, con-
struction, and gardening) nor contact with swine, cattle, or 
rodents was linked to severity (Table 1). Nine host-related 
factors (listed in order of decreasing odds ratio) remained 
independently associated with severity in the multivariate 
analysis: history of chronic hypertension, hyperamylasemia, 
history of chronic alcoholism, abnormalities at chest aus-
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Table 1. Demographic, epidemiologic, and clinical characteristics as a function of severity among 168 case-patients with confirmed
leptospirosis, Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, 2003–2004* 
Univariate analysis† 
Multivariate analysis 
Characteristics
All case-
patients,
N = 168 
Case-patients
with severe 
disease, n = 24 
Case-patients
with nonsevere 
disease, n = 144  p value  OR (95% CI)  p value 
Male sex  143/168 (85.1)  18/24 (75)  125/144 (86.8)  0.2 2.6 (0.4–17.7)  0.3
Age, y, mean ± SD (no. patients) 
  F  58.5 ± 17.9 (25)  55.5 ± 2.4 (6)  36.7 ± 8 (19)  0.05
  M  47 ± 15.9 (143)  51.8 ± 6.5 (18)  49.6 ± 2.9 (125)  0.5
Exposure to occupational risk‡  74/133 (55.6)  12/20 (60)  62 /113 (54.8)  0.6
Contact with swine  41/115 (35.6)  5/10 (50)  36/105 (34.2)  0.5
Contact with cattle  36/113 (31.9)  1/10 (10)  35/103 (34)  0.8
Contact with rodents  56/114 (49.1)  3/9 (33.3)  53/105 (50.5)  0.5
Medical history 
  Duration of illness before  
  antibacterial therapy§ >10 d
21/141 (14.9)  7/22 (31.8)  14/119 (11.8)  0.01 4.8 (1.1–20.2)  0.032
  Diabetes mellitus  13/75 (17.3)  3/22 (13.6)  10/53 (18.9)  0.5
  Chronic hypertension ¶  24/75 (32)  9/22 (40.9)  15/53 (28.3)  0.2 30.9 (6.0–157.4) <0.001
  Chronic alcoholism#  29/75 (38.7)  11/22 (50.0)  18/53 (34)  0.2 16.8 (4.1–57.9)  <0.001
Initial features 
  Hypothermia (<36.5°C)  28/144 (19.4)  7/23 (30.4)  21/121 (17.3)  0.1 4.6 (0.9–24.6)  0.07
  Hyperthermia (>37.7°C)  82/144 (56.9)  10/23 (43.5)  72/121 (59.5)  0.1 3.8 (0.7–21.2)  0.12
  Hypotension, SBP <100 mm Hg  24/143 (16.8)  7/20 (35)  17/123 (13.8)  0.02 0.3 (0.1–1.8)  0.2
  Myalgia  73/77 (94.8)  12/13 (92.3)  61/64 (95.3)  0.6
  Consciousness disorders  10/119 (8.4)  4/13 (30.8)  6/106 (5.7)  0.01 3.8 (1.1–13.2)  0.035
  Nuchal rigidity  10/116 (8.6)  2/12 (16.7)  8/104 (7.7)  0.2
  Headache  70/91 (76.9)  5/7 (71.4)  65/84 (77.4)  0.7
  Conjunctival suffusion  46/116 (39.6)  4/12 (33.3)  42/104 (40.4)  0.4
  Icterus  57/117 (48.7)  9/12 (75)  48/105 (45.7)  0.1 5.9 (1.1–31.1)  0.036
  Hemorrhage**  15/165 (9.1)  5/24 (20.8)  10/141 (7.1)  0.04 4.2 (0.3–67.9)  0.31
  Hepatosplenomegaly  30/86 (34.9)  7/11 (63.6)  23/75 (30.7)  0.02 1.7 (0.2–13.9)  0.62
  Abdominal pain  64/124 (51.6)  14/18 (77.8)  50/106 (47.2)  0.009 3 (0.7–13.2)  0.139
  Digestive disorders (diarrhea,  
 vomiting) 
66/105 (62.8)  12/15 (80)  54/90 (60)  0.2 3.5 (0.7–18.0)  0.12
  Abnormalities at chest  
 auscultation††
19/135 (14.1)  8/17 (47)  11/118 (9.3)  <0.001 8.7 (1.8–41.3)  0.006
  Chest radiologic anomalies‡‡  22/112 (19.6)  6/16 (37.5)  16/96 (16.7)  0.05 0.8 (0.1–10.4)  0.85
  Alveolar infiltrate  9/112 (8.0)  5/16 (31.2)  4/96 (4.2)  <0.001
  Electrocardiographic disorders§§  22/73 (30.1)  5/16 (31.2)  17/57 (29.8)  0.9
  Oliguria¶¶ or anuria  34/128 (26.6)  10/23 (43.5)  24/105 (22.9)  0.04 5.6 (1.5–20.6)  0.009
*OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure. Boldface indicates significance.  
†All values no. case-patients/no. examined (%) except as indicated. 
‡Farming, livestock farming, construction, and gardening. 
§Ampicillin or cefotaxime. 
¶As reported by patients with specific therapy. 
#Defined as alcohol dependence. 
**Hemoptysis, hematuria, purpura, bleeding of the gums, and hematemesis. 
††Crackles or ronchi. 
‡‡Only anomalies of the lungs. 
§§Excluding patients >60 y of age or with sinus tachycardia. 
¶¶Urinary volume <400 mL/d. Severe Leptospirosis, Guadeloupe
cultation, oligoanuria, late initiation (>10 days after onset 
of symptoms) of antibacterial therapy, elevated aspartate 
aminotransferase levels, consciousness disorders, and ict-
erus. Chronic alcoholism was linked to death (p<0.01). The 
L. interrogans serovar Icterohemorrhagiae was isolated in 
75% of severe cases, but in only 38% of nonsevere cases, 
and was independently associated with severity.
Conclusions
The potential correlation between disease severity 
and Leptospira serovar remains a matter of debate. The 
L.  interrogans serovars Icterohemorrhagiae, Canicola, 
and Australis have been linked to severity and multiorgan 
failure (6–8), but other studies did not conﬁ  rm any link 
between serovar and outcome (9–11).  L. Icterohemor-
rhagiae was clearly linked to disease severity. Therefore, 
a diagnostic test speciﬁ  cally detecting this serovar at an 
early stage of disease could help in the management of 
leptospirosis in patients in Guadeloupe. We conﬁ  rmed 
that the L. borgpetersenii serovars Arborea and Castel-
lonis, rarely isolated elsewhere, are highly prevalent in 
Guadeloupe (3,12). Taken together, they are the second 
most prevalent serovars after Icterohemorrhagiae. Nota-
bly, the serogroup Ballum, comprising the serovars Ar-
borea and Castellonis, also is one of the main serogroups 
associated with human infections in Barbados (9). The se-
rovar Arborea has been associated with mice, particularly 
in Barbados (1,13). In Guadeloupe, this serovar has been 
isolated from mice and rats, and the serovars Icterohemor-
rhagiae and Bogvere have been isolated from rats (3; V. 
Michelle, pers. comm.). Thus, rodent populations may be 
the main source of Leptospira spp. in Guadeloupe. Fur-
ther animal studies are needed to establish the nature of 
these Leptospira reservoirs.
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Table 2. Laboratory findings for 168 case-patients with confirmed leptospirosis, Hospital of Pointe-à-Pitre, Guadeloupe, French West 
Indies, 2003–2004* 
Univariate analysis 
Multivariate analysis 
Laboratory findings 
All case-patients, 
N = 168† 
Case-patients
with severe 
disease, n = 24†
Case-patients with 
nonsevere disease, 
n = 144†  p value  OR (95% CI)  p value 
Prothrombin time <70%  10/118 (8.5)  5/21 (23.8)  5/97 (5.1)  0.01 0.7 (0.05–9.8)  0.077
Thrombocytopenia, <50 × 10
9
cells/L
25/135 (18.5)  8/23 (34.8)  17/112 (15.2)  0.02 1 (0.1–2.4)  0.96
Hyperneutrophilia, >12 × 10
9
cells/L
24/136 (17.6)  10/23 (43.5)  14/113 (12.4)  0.01 0.9 (0.1–7.1)  0.93
ALT >119 U/L  30/108 (27.8)  6/23 (26.1)  24/85 (28.2)  0.8
AST >102 U/L  58/128 (45.3)  17/23 (73.9)  41/105 (39)  0.02 4.3 (1.2–14.6)  0.021
CPK >1000 U/L  22/108 (20.4)  5/18 (27.8)  17/90 (18.9)  0.4
LDH >800 U/L  11/101 (10.9)  3/17 (17.6)  8/84 (9.5)  0.3
Amylase >285 U/L  16/82 (19.5)  8/15 (53.3)  8/67 (11.9)  <0.001 18.5 (3.8–88.8)  <0.001
Lipase >60 U/L  7/40 (17.5)  2/8 (25)  5/32 (15.6)  0.8
Hemoglobin, g/dL  12.9 ± 0.6 (136)  11.1 ± 2.0 (23)  13.2 ± 3.4 (113)  0.01
  Hemoglobin <10 g/dL  13/136 (9.5)  5/23 (21.7)  8/113 (7.1)  0.04 2.3 (0.5–9.8)  0.2
Bilirubin, mg/dL  8.3 ± 2.3 (86)  15.2 ± 11.7 (18)  5.8 ± 7.2 (68)  <0.001
  Bilirubin >7 mg/dL  31/86 (36.0)  13/18 (72.2)  18/68 (26.4)  <0.001 0.48 (0.05–4.7)  0.6
Potassium, mmol/L  4.0 ± 0.22 (136)  3.8±.9 (23)  4.0 ± 1.3 (113)  0.5
Sodium, mmol/L  133.5 ± 4.2 (136)  132.8 ± 5.3 (23)  133.6 ± 3.9 (113)  0.5
Creatinine, mg/d  2.0 ± 0.3 (130)  2.8 ± 2.5 (21)  1.9 ± 2.0 (109)  0.05 2.0 (0.6–6.6)  0.2
  Creatinine >1.5 mg/dL  54/130 (41.5)  11/21 (52.4)  43/109 (39.4)  0.2
Urea nitrogen mg/dL  69.0 ± 10.2 (136)  85.8 ± 76.2 (23)  64.2 ± 64.2 (113)  0.5
Isolation of Leptospira in
blood culture 
55/88 (62.5)  8/14 (57.1)  47/74 (63.5)  0.3
 L.  interrogans serovar  
 Icterohemorrhagiae
18/40‡ (45)  6/8 (75)  12/32 (37.5)  0.06 5.3 (1.0–26.0)  0.004
 L.  borgpetersenii serovar  
 Castellonis
5/40‡ (12.5)  0/8 5/32 (15.6)  0.1
 L.  borgpetersenii serovar 
 Arborea 
9/40‡ (22.5)  2/8 (25)  7/32 (21.9)  0.6
 L.  kirschneri serovar  
 Bogvere 
6/40‡ (15)  0/8 6/32 (18.7)  0.1
 L.  santarosai serovar  
 Tabaquite 
2/40‡ (5)  0/8 2/8 (25)  0.4
*OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatinine phosphokinase; LDH, lactate 
dehydrogenase. Boldface indicates significance. 
†Mean ± SD (examined) or no. case-patients/no. examined (%).  
‡Serovar identification was completed for 40 of the 55 Leptospira strains isolated. Chronic hypertension has not previously been found to 
predict poor prognosis for leptospirosis. Here, we found it 
to be the strongest risk factor for severe disease. Whether 
patients with histories of chronic hypertension are especial-
ly susceptible remains to be conﬁ  rmed.
In our series of patients, acute hepatitis and pancrea-
titis were severe complications of leptospirosis in those 
with chronic alcoholism; chronic alcoholism itself was an 
independent indicator of poor prognosis. These results are 
consistent with ﬁ  ndings from other studies conducted in La 
Réunion, another French overseas territory, and in conti-
nental France (14,15).
Patients with chronic hypertension or chronic alcohol-
ism, late initiation of antibacterial therapy, consciousness 
disorders, abnormal features at chest auscultation, oligoa-
nuria, jaundice, hyperamylasemia, or high aspartate ami-
notransferase levels may beneﬁ  t from early intensive and 
speciﬁ  c management. The predominance of the Icterohe-
morrhagiae serovar, linked to severe disease, and of the 
Arborea and the Castellonis serovars highlights the need 
for rodent control to reduce the effects of leptospirosis in 
Guadeloupe.
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